Jean Merot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jean Merot has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Jacques Schott
Nantes Université, CHU Nantes, CNRS, INSERM, l’institut du thorax , F-44000 Nantes
7 shared publications - Thierry Le Tourneau
Nantes Université, CHU Nantes, CNRS, INSERM, l’institut du Thorax, Nantes, France
7 shared publications Florence Kyndt
5 shared publicationsSimon Lecointe
Nantes Université, CHU Nantes, CNRS, INSERM, l’institut du thorax , F-44000 Nantes , France
5 shared publicationsAntoine Rimbert
4 shared publications- Damien Duval
Institut du thorax, Inserm UMR 1087, CNRS UMR 6291, 8 Quai Moncousu, Nantes F-44007, France
4 shared publications
Latest Publications
- 24 August 2022
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 119 (3) , 759-771
Multimodality imaging and transcriptomics to phenotype mitral valve dystrophy in a unique knock-in Filamin-A rat model
Degenerative mitral valve dystrophy (MVD) leading to mitral valve prolapse is the most frequent form of MV disease, and there is currently no pharmacological treatment available. The limited understanding of the pathophysiological mechanisms leading to MVD limits our ability to identify therapeutic targets. This study aimed to reveal the main pathophysiological pathways involved in MVD via the multimodality imaging and transcriptomic analysis of the new and unique knock-in (KI) rat model for the FilaminA-P637Q (FlnA-P637Q) mutation associated-MVD. Wild-type (WT) and KI rats were evaluated morphologically, functionally, and histologically between 3-week-old and 3-to-6-month-old based on Doppler echocardiography, 3D micro-computed tomography (microCT), and standard histology. RNA-sequencing and Assay for Transposase-Accessible Chromatin (ATAC-seq) were performed on 3-week-old WT and KI mitral valves and valvular cells, respectively, to highlight the main signalling pathways associated with MVD. Echocardiographic exploration confirmed MV elongation (2.0 ± 0.1 mm vs. 1.8 ± 0.1, P = 0.001), as well as MV thickening and prolapse in KI animals compared to WT at 3 weeks. 3D MV volume quantified by microCT was significantly increased in KI animals (+58% vs. WT, P = 0.02). Histological analyses revealed a myxomatous remodelling in KI MV characterized by proteoglycans accumulation. A persistent phenotype was observed in adult KI rats. Signalling pathways related to extracellular matrix homeostasis, response to molecular stress, epithelial cell migration, endothelial to mesenchymal transition, chemotaxis and immune cell migration, were identified based on RNA-seq analysis. ATAC-seq analysis points to the critical role of transforming growth factor-β and inflammation in the disease. The KI FlnA-P637Q rat model mimics human myxomatous MVD, offering a unique opportunity to decipher pathophysiological mechanisms related to this disease. Extracellular matrix organization, epithelial cell migration, response to mechanical stress, and a central contribution of immune cells are highlighted as the main signalling pathways leading to myxomatous MVD. Our findings pave the road to decipher underlying molecular mechanisms and the specific role of distinct cell populations in this context.
- 24 August 2022
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 119 (3) , 759-771
Multimodality imaging and transcriptomics to phenotype mitral valve dystrophy in a unique knock-in Filamin-A rat model
Degenerative mitral valve dystrophy (MVD) leading to mitral valve prolapse is the most frequent form of MV disease, and there is currently no pharmacological treatment available. The limited understanding of the pathophysiological mechanisms leading to MVD limits our ability to identify therapeutic targets. This study aimed to reveal the main pathophysiological pathways involved in MVD via the multimodality imaging and transcriptomic analysis of the new and unique knock-in (KI) rat model for the FilaminA-P637Q (FlnA-P637Q) mutation associated-MVD. Wild-type (WT) and KI rats were evaluated morphologically, functionally, and histologically between 3-week-old and 3-to-6-month-old based on Doppler echocardiography, 3D micro-computed tomography (microCT), and standard histology. RNA-sequencing and Assay for Transposase-Accessible Chromatin (ATAC-seq) were performed on 3-week-old WT and KI mitral valves and valvular cells, respectively, to highlight the main signalling pathways associated with MVD. Echocardiographic exploration confirmed MV elongation (2.0 ± 0.1 mm vs. 1.8 ± 0.1, P = 0.001), as well as MV thickening and prolapse in KI animals compared to WT at 3 weeks. 3D MV volume quantified by microCT was significantly increased in KI animals (+58% vs. WT, P = 0.02). Histological analyses revealed a myxomatous remodelling in KI MV characterized by proteoglycans accumulation. A persistent phenotype was observed in adult KI rats. Signalling pathways related to extracellular matrix homeostasis, response to molecular stress, epithelial cell migration, endothelial to mesenchymal transition, chemotaxis and immune cell migration, were identified based on RNA-seq analysis. ATAC-seq analysis points to the critical role of transforming growth factor-β and inflammation in the disease. The KI FlnA-P637Q rat model mimics human myxomatous MVD, offering a unique opportunity to decipher pathophysiological mechanisms related to this disease. Extracellular matrix organization, epithelial cell migration, response to mechanical stress, and a central contribution of immune cells are highlighted as the main signalling pathways leading to myxomatous MVD. Our findings pave the road to decipher underlying molecular mechanisms and the specific role of distinct cell populations in this context.
- 1 July 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1864 (7) , 1142-1152
The alternatively spliced LRRFIP1 Isoform-1 is a key regulator of the Wnt/β-catenin transcription pathway
- 1 July 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1864 (7) , 1142-1152
The alternatively spliced LRRFIP1 Isoform-1 is a key regulator of the Wnt/β-catenin transcription pathway
- 1 January 2016
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 8 (1) , 52
0131: A phenotypic study of ARHGAP24 mitral valve prolapse suggests a genetic origin for fibro elastic deficiency
- 1 January 2016
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 8 (1) , 52
0131: A phenotypic study of ARHGAP24 mitral valve prolapse suggests a genetic origin for fibro elastic deficiency
- Open Access
- 8 September 2015
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 2 (3) , 233-247
MVP-Associated Filamin A Mutations Affect FlnA-PTPN12 (PTP-PEST) Interactions
Although the genetic basis of mitral valve prolapse (MVP) has now been clearly established, the molecular and cellular mechanisms involved in the pathological processes associated to a specific mutation often remain to be determined. The FLNA gene (encoding Filamin A; FlnA) was the first gene associated to non-syndromic X-linked myxomatous valvular dystrophy, but the impacts of the mutations on its function remain un-elucidated. Here, using the first repeats (1–8) of FlnA as a bait in a yeast two-hybrid screen, we identified the tyrosine phosphatase PTPN12 (PTP-PEST) as a specific binding partner of this region of FlnA protein. In addition, using yeast two-hybrid trap assay pull down and co-immunoprecipitation experiments, we showed that the MVP-associated FlnA mutations (G288R, P637Q, H743P) abolished FlnA/PTPN12 interactions. PTPN12 is a key regulator of signaling pathways involved in cell-extracellular matrix (ECM) crosstalk, cellular responses to mechanical stress that involve integrins, focal adhesion transduction pathways, and actin cytoskeleton dynamics. Interestingly, we showed that the FlnA mutations impair the activation status of two PTPN12 substrates, the focal adhesion associated kinase Src, and the RhoA specific activating protein p190RhoGAP. Together, these data point to PTPN12/FlnA interaction and its weakening by FlnA mutations as a mechanism potentially involved in the physiopathology of FlnA-associated MVP.
- 8 September 2015
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 2 (3) , 233-247
Open AccessMVP-Associated Filamin A Mutations Affect FlnA-PTPN12 (PTP-PEST) Interactions
Although the genetic basis of mitral valve prolapse (MVP) has now been clearly established, the molecular and cellular mechanisms involved in the pathological processes associated to a specific mutation often remain to be determined. The FLNA gene (encoding Filamin A; FlnA) was the first gene associated to non-syndromic X-linked myxomatous valvular dystrophy, but the impacts of the mutations on its function remain un-elucidated. Here, using the first repeats (1–8) of FlnA as a bait in a yeast two-hybrid screen, we identified the tyrosine phosphatase PTPN12 (PTP-PEST) as a specific binding partner of this region of FlnA protein. In addition, using yeast two-hybrid trap assay pull down and co-immunoprecipitation experiments, we showed that the MVP-associated FlnA mutations (G288R, P637Q, H743P) abolished FlnA/PTPN12 interactions. PTPN12 is a key regulator of signaling pathways involved in cell-extracellular matrix (ECM) crosstalk, cellular responses to mechanical stress that involve integrins, focal adhesion transduction pathways, and actin cytoskeleton dynamics. Interestingly, we showed that the FlnA mutations impair the activation status of two PTPN12 substrates, the focal adhesion associated kinase Src, and the RhoA specific activating protein p190RhoGAP. Together, these data point to PTPN12/FlnA interaction and its weakening by FlnA mutations as a mechanism potentially involved in the physiopathology of FlnA-associated MVP.
- 1 January 2015
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 7 (1) , 51
0493: Mutations in the gene encoding FilGAP as a cause for mitral valve prolapse
- 1 January 2015
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 7 (1) , 51
0493: Mutations in the gene encoding FilGAP as a cause for mitral valve prolapse
- 1 April 2014
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 6, 72-73
0030: ARHGAP 24/ (FilGAP); a new gene responsible for mitral valve prolapse
- 1 April 2014
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 6, 72-73
0030: ARHGAP 24/ (FilGAP); a new gene responsible for mitral valve prolapse
- 1 April 2014
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 6, 72
0174: LRRFip1 and Wnt pathway involvement in mitral valve prolapse
- 1 April 2014
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 6, 72
0174: LRRFip1 and Wnt pathway involvement in mitral valve prolapse
- 4 November 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1843 (2) , 234-244
Valvular dystrophy associated filamin A mutations reveal a new role of its first repeats in small-GTPase regulation
- 4 November 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1843 (2) , 234-244
Valvular dystrophy associated filamin A mutations reveal a new role of its first repeats in small-GTPase regulation